Adlai NortyeANL -1.82% Return-on-Tangible-Equity is 0.00% as of Dec. 2025. The stock has 7 warning signs investors should review. Among 1,195 Biotechnology companies, Adlai Nortye ranks worse than 94.39% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Adlai Nortye's annualized net income for the quarter that ended in Dec. 2025 was $-34.39 Mil. Adlai Nortye's average shareholder tangible equity for the quarter that ended in Dec. 2025 was $-0.22 Mil. Therefore, Adlai Nortye's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was N/A%.
The historical rank and industry rank for Adlai Nortye's Return-on-Tangible-Equity or its related term are showing as below:
ANL'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -426.4 Med: -259.37 Max: -103.3
Current: -426.4
During the past 5 years, Adlai Nortye's highest Return-on-Tangible-Equity was -103.30%. The lowest was -426.40%. And the median was -259.37%.
ANL's Return-on-Tangible-Equity is ranked worse than 94.39% of 1195
companies
in the Biotechnology industry
Industry Median: -42.21
vs ANL: -426.40
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Adlai Nortye Return-on-Tangible-Equity Related Terms
Adlai Nortye Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Adlai Nortye's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ANL vs OMER, PRME, DNA: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Adlai Nortye's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adlai Nortye Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adlai Nortye's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Adlai Nortye's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 0.00% mean?
Adlai Nortye (ANL) has a Return-on-Tangible-Equity of 0.00% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Adlai Nortye and its competitors. According to the industry distribution chart, Adlai Nortye ranks #1128 out of 1195 companies in the Biotechnology industry, placing it in the top 94.4%.
Is Adlai Nortye's Return-on-Tangible-Equity too high?
Adlai Nortye's current Return-on-Tangible-Equity is 0.00%. Based on the distribution chart, Adlai Nortye ranks #1128 out of 1195 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Adlai Nortye's Return-on-Tangible-Equity compare to OMER and PRME?
According to the Biotechnology industry distribution chart, Adlai Nortye ranks #1128 out of 1195 companies for Return-on-Tangible-Equity. This places Adlai Nortye in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Adlai Nortye and its competitors. Adlai Nortye's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adlai Nortye stock overvalued right now?
Adlai Nortye (ANL) has a current Return-on-Tangible-Equity of 0.00%. The current Return-on-Tangible-Equity is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Adlai Nortye (ANL), the current Return-on-Tangible-Equity is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANL has been successfully added to your 